DCVax-L regulatory update

Northwest Biotherapeutics said Germany's Paul Ehrlich Institute (PEI) approved a "hospital exemption" early access program for DCVax- L to treat newly diagnosed and recurrent glioma. According to the company, Germany's Institute for the Hospital Remuneration System (InEK) said hospitals may apply for reimbursement of DCVax-L. The company said it will now negotiate a price for DCVax-L with hospitals and health insurance funds, which will be applied to patients on a case-by-case basis, and that patients may self-pay for DCVax-L in the interim. The company said it cannot actively market the product under the program. ...